A clinical case of successful application of a new treatment method for severe COVID-19

• Main Authors: Alexander S. Samoylov, Yuri D. Udalov, Nikolai M. Kruglyakov, Dmitry А. Terekhov, German I. Bagzhanov, Sergey S. Ochkin
• Format: Article
• Language: Russian
• Published: Eco-vector 2020-08-01
• Series: Клиническая практика
• Subjects: covid-19; selective plasma filtration; immunosuppression; plasma exchange; case report
• Online Access: https://journals.eco-vector.com/clinpractice/article/viewFile/34529/pdf_1

COVID-19, formerly coronavirus infection 2019-nCoV, is a potentially severe acute respiratory infection caused by the SARS-CoV-2 coronavirus (2019-nCoV). It is a dangerous disease that can occur both in the form of a mild acute respiratory viral infection and in a severe form with the development of bilateral polysegmental viral pneumonia, specific complications of which may include acute respiratory distress syndrome, resulting in the respiratory failure with a high risk of death. Due to the absence of etiotropic therapy for the coronavirus infection, pathogentic treatment becomes of primary importance. We present a clinical case of a severe form of COVID-19 in a 33-year-old man to whom we administered a new method of pathogenetic treatment of this disease based on immunosuppresiive therapy followed by therapeutic plasma exchange and infusion of non-specific human immunoglobulin.